ASSESSING MUCOSAL RECOVERY DURING THE FIRST 15 MONTHS OF ADOPTING A GLUTEN-FREE DIET IN CHILDREN WITH CELIAC DISEASE.

Objective: Determine contemporary rates of early mucosal recovery in children with celiac disease (CeD).

Methods: Multicenter retrospective cohort study in Canada and the United States. Children diagnosed with CeD between 2016 and 2021 who underwent a follow-up biopsy within 15 months of diagnosis were included.

Care for adolescents with drug-susceptible pulmonary tuberculosis in Lima, Peru: a qualitative assessment.

Objective: To identify the barriers and facilitators of adolescent-friendly tuberculosis (TB) services among adolescents with drug-susceptible TB (DS-TB), as defined by the WHO's Adolescent-Friendly Services (AFS) framework, in Lima, Peru.

Design: We conducted in-depth interviews using semistructured interview guides. Data were analysed using the framework method, in which themes were mapped onto four of the five dimensions of care in the WHO's AFS framework: accessibility, acceptability, appropriateness and effectiveness.

Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.

Introduction: CD47 is highly expressed on cancer cells and triggers an anti-phagocytic "don't eat me" signal when bound by the inhibitory signal regulatory protein α (SIRPα) expressed on macrophages. While CD47 blockade can mitigate tumor growth, many CD47 blockers also bind to red blood cells (RBCs), leading to anemia. Maplirpacept (TTI-622, PF-07901801) is a CD47 blocking fusion protein consisting of a human SIRPα fused to an IgG4 Fc region and designed to limit binding to RBCs.

A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study).

In view of the limited data related to preemptive pharmacogenomics (PGx) testing in the primary care setting, we designed a study to assess the feasibility of implementing preemptive PGx services at outpatient clinics, with the aim to assess the practicality and challenges of implementing preemptive PGx testing within primary care, and its impact on clinical workflows and patient care. This prospective study was conducted between October 2022 and August 2023 at five outpatient clinics located in Singapore. Patients aged 21 to 65 with a reported history or risk of developing any of the target chronic conditions or any patients receiving one of the 29 PGx-associated medications were recruited.